COPD patients with higher levels of eosinophils are more at risk of experiencing a cardiac event if not receiving an inhaled corticosteroid (ICS) as part of their therapy, according to a post hoc analysis of data from the ETHOS trial. Presenting the findings at ERS 2021, Professor Mona Bafadhel, Respiratory Physician and COPD research group ...
ICS therapy shows most CV benefit in COPD patients with eosinophilia
By Selina Wellbelove
14 Sep 2021